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Abstract
Neurotensin (NTS), a 13–amino acid peptide which is distributed predominantly along gastrointestinal tract, has
multiple physiologic and pathologic functions, and its effects are mediated by three distinct NTS receptors
(NTSRs). Overexpression and activation of NTS signaling components, especially NTS and/or NTSR1, are closely
linked with cancer progression and metastasis in various types of cancers including neuroendocrine tumors
(NETs). Although deregulation of NTSR3/sortilin has been implicated in a variety of human diseases, the
expression and role of NTSR3/sortilin in NETs have not been elucidated. In this study, we investigated the
expression and oncogenic effect of NTSR3/sortilin in NETs. Increased protein levels of NTSR3/sortilin were noted
in the majority of human clinical NETs (n = 21) by immunohistochemical analyses compared with normal tissues
(n = 12). Expression of NTS andNTSR3/sortilin was also noted in all testedNET cell lines. In addition, small interfering
RNA–mediated knockdown of NTSR3/sortilin decreased cell number without alteration of cell cycle progression and
apoptosis induction in NET cell lines BON and QGP-1. Moreover, silencing of NTSR3/sortilin significantly suppressed
cell adhesion and cell migration with inhibition of focal adhesion kinase and Src phosphorylation in the NET cells. Our
results demonstrate increased expression of NTSR3/sortilin in NET patient tissues and a critical role of NTSR3/sortilin
on NET cell adhesion and migration suggesting that NTSR3/sortilin contributes to NET tumorigenesis.
Neoplasia (2018) 20, 175–181
Introduction
Neuroendocrine tumors (NETs) are rare and slow-growing tumors,
but recent studies indicate that they are increasing in incidence [1,2].
NETs originate in the diffuse endocrine system and are capable of
producing and secreting bioreactive peptides, neuroamines, and
hormones [2,3]. Some of the vasoactive substances (e.g., serotonin)
are associated with specific clinical syndromes characterized by
flushing, diarrhea, and heart disease and are used as diagnostic
biomarkers or therapeutic targets for NETs [2,3]. Several peptide
receptors are also expressed in many cancers and appear promising as a
diagnostic marker as well as a potential therapeutic target [4,5].
Neurotensin (NTS), a tridecapeptide, has multiple physiological
functions including proliferation of normal intestinal mucosa [6,7].
Furthermore, NTS modulates intestinal inflammation and augments
the growth of many cancers [6,8]. The physiopathological effects of
NTS are triggered by interaction with three distinct receptors: two G
protein–coupled receptors, high-affinity NTSR1 and low-affinity
NTSR2, and a single transmembrane domain receptor, NTR3/
sortilin [8]. In particular, NTSR1, which is highly expressed in a
variety of solid tumors, mediates the effects of NTS on cell
proliferation, survival, migration, and invasion through multiple
signaling pathways such as PKC and MAPK activation [8–10].
NTSR3/sortilin, which is also a member of the Vps10p sorting
receptor family, is expressed in a wide range of cell types and tissues
[11–14]. It plays important roles in various biological processes such
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as the transport of a variety of intracellular proteins and works as the
co-receptor for the precursor of nerve growth factor (pro-NGF) and
the 75-kDa neurotrophin receptor (p75NTR), or a regulator of
atherosclerosis [11,13]. Deregulation of NTSR3/sortilin function has
been implicated in a variety of human diseases including cardiovas-
cular disease and cancer [11–13]. Elevated expression NTSR3/sortilin
is also found in some types of human cancer cells and tissues
including brain, breast, and prostate, which suggests a role for this
protein in tumorigenesis [13,15–18].
Recently, we found that NTS stimulates the growth of NET cells
as a target of the Wnt/β-catenin pathway [19]. In addition, we
showed increased expression of NTSR1 in NETs and oncogenic
functions of NTSR1 such as cell growth, attachment, migration, and
invasion in NET cell lines [9]. Although consistent expression of
NTSR3/sortilin is noted in NET cells, expression of NTSR3/sortilin
in patient tissues and its roles in tumorigenesis have not been clearly
elucidated in NETs. In our present study, we analyzed the expression
of NTSR3/sortilin in clinical NET tissues and cell lines. Moreover,
we delineated the tumorigenic functions of NTSR3/sortilin on NET
cell adhesion and migration. Based on our findings, notably increased
expression in NET patient tissues and promotion of cell adhesion and
migration, NTSR3/sortilin appears to contribute to NET tumori-
genesis and may possibly serve as a therapeutic target.
Materials and Methods
Immunohistochemistry
The slides, which were used in previous studies [9,20], were provided
by the University of Kentucky Department of Pathology and the
Markey Cancer Center Biospecimen Procurement and Translational
Pathology Shared Resource Facility. Immunostaining was carried out as
described previously [9,20] with an antibody against NTSR3/sortilin
purchased from Alomone Labs (Jerusalem, Israel).
Cell Culture and siRNA Transfections
Four human NET cell lines, BON, QGP-1, NCI-H727, and
UMC-11, were used as described previously [9,19,20]. The cell lines
were authenticated by STR profiling in March and May 2016 by
Genetica DNA Laboratories (LabCorp Specialty Testing Group,
Burlington, NC). Transfection with nontargeting control and
SMARTPool NTSR3/sortilin siRNA (Dharmacon, Lafayette, CO)
was performed as previously described [9].
RNA Isolation and Quantitative Reverse Transcription
Polymerase Chain Reaction (qRT-PCR) Analysis
Total RNA isolation and qRT-PCR were carried out as described
previously [9]. Expression levels of NTS and NTSR3/sortilin were
normalized to GAPDH.
Western Blot Analysis
Western blotting was carried out as described previously [9]. The
antibodies for proliferating cell nuclear antigen (PCNA) and β-actin were
obtained from Santa Cruz Biotechnology (Dallas, TX) and Sigma-Aldrich
(St. Louis, MO), respectively. The antibodies for poly (ADP-ribose)
polymerase (PARP), focal adhesion kinase (FAK), phospho-FAK (Tyr397),
Src, and phospho-Src (Tyr416) were from Cell Signaling (Danvers, MA).
Cell Counting and Apoptosis Analysis
Cell counting and apoptosis analyses were performed as described
previously [9,20].
Cell Cycle Analysis by Flow Cytometry
TransfectedNET cells were collected by trypsinization, washed, fixed
with 70% ice-cold ethanol, and stored at −20°C until analysis by flow
cytometry. The fixed cells were washed, resuspended in FxCycle
Propidium iodide/RNase staining solution (Life Technologies,
Carlsbad, CA), and incubated for 15 to 30 minutes in the dark. The
UK Flow Cytometry Service Facility conducted cell cycle analysis using
the Becton-Dickinson FACSort flow cytometer (BD Biosciences, NJ).
The cell cycle data were analyzed using CellQuest program (BD
Biosciences) to determine the percentage of cells at different stages of the
cycle (G1, S, and G2/M).
Adhesion Assay
A cell adhesion assay was performed to assess cell binding ability to
direct or the extracellular matrix (ECM)–coated culture plate as
described previously [9]. Briefly, equal numbers of detached NET cells
were plated to each uncoated well or type I collagen–coated well of
48-well plates and incubated for 6 hours or 30 minutes, respectively.
Transwell Migration Assay
A Boyden chamber migration assay carried out with control and
NTSR3/sortilin knockdown NET cells as described previously [9].
The chambers were incubated at 37°C for 24 or 48 hours,
respectively, and the cells were fixed with methanol and stained
with 0.5% crystal violet in 20% methanol.
Statistical Analysis
Descriptive statistics for immunoreactivity score, mRNA levels, cell
counts, and apoptosis were calculated according to experimental
groups. Correlations between NTSR1 versus NTSR3/sortilin were
assessed using Spearman's correlation coefficient. Pairwise compar-
isons were performed using two-sample t test and multiple group
comparisons using analysis of variance with adjustment for multiple
testing based on Holm's P value adjustment method.
Results
Expression Analysis of NTSR3/Sortilin in NET Tissues and
Cell Lines
Although a number of studies, including those from our laboratory,
have demonstrated increased expression of NTS and NTSR1 in many
tumor types including NETs [8–10], the expression of NTSR3/sortilin
has not been well studied in NETs. To assess NTSR3/sortilin expression,
immunohistochemistry was performed using clinical NET patient samples
(13 gastrointestinal [GI], 6 lung and 2 thymus tissues) whichwere analyzed
for β-catenin and NTSR1 in our previous reports [9,20]. Statistical
comparisons of immunoreactivity scores between normal (5 GI, 5 lung,
and 2 thymus tissues) versus NETs showed significantly increased
expression of NTSR3/sortilin in 9 GI and in all lung and thymus NET
samples (Figure 1A). An analysis of the possible relationship between
NTSR1 and NTSR3/sortilin expression was also carried out due to high
expression levels of these receptors in the NET samples. There was little to
no correlation in the NET samples (Spearman correlation = − 0.0075,
P = .975; data not shown). In addition, predominant cytoplasmic staining
of NTSR3/sortilin was observed in NET tissues, suggesting localization in
intracellular organelles, such as the Golgi body and endoplasmic reticulum
(Figure 1B).
In addition, to evaluate quantitative expression of NTS and
NTSR3/sortilin, endogenous levels of mRNA and protein were also
checked by qRT-PCR and Western blotting, respectively. All tested
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NET cell lines demonstrated varying levels of mRNA expression for
NTS and NTSR3/sortilin by qRT-PCR analysis (Figure 1C). By
comparison with respective NET cells, higher expression levels of
NTS were noted in QGP-1 and NCI-H727 cells, whereas increased
expression of NTSR3/sortilin was detected in BON and UMC-11
compared with QGP-1 and NCI-H727 cells (Figure 1C). Consistent
with mRNA expression levels, the protein expression of NTS and
NTSR3/sortilin was confirmed in the four human NET cells by
Western blotting (Figure 1D). Overall, all NET cell lines expressed
NTS and NTSR3/sortilin proteins which closely approximated the
mRNA expression levels of the corresponding genes.
The Effect of NTSR3/Sortilin Knockdown on NET Cell Number
Recently, we have shown that inhibition of NTS or NTSR1
suppressed tumorigenic functions in NET cells [9,19]. To elucidate
the potential role of NTSR3/sortilin in NET cells, we used small
interfering RNA (siRNA) against NTSR3/sortilin in BON and
QGP-1 cells and determined the effect on cell number by direct cell
counting. Knockdown of NTSR3/sortilin decreased BON and
QGP-1 cell numbers at 48 and 96 hours compared with cells
transfected with nontargeting control siRNA (Figure 2A). Further-
more, we determined the levels of PCNA and PARP cleavage, which
were used as markers for cell proliferation [21] and apoptosis [22],
respectively, since change in cell number may be related to a decrease
in cell cycle progression and/or induction of apoptosis. NTSR3/
sortilin silencing did not change the level of PCNA and induce
cleaved PARP in either BON or QGP-1 cells as noted by Western
blot analysis (Figure 2A).
As a next step,wedirectlymeasured cell cycle progression and apoptosis in
the cells under basal culture conditions. Flow cytometric analysis
using propidium iodide staining demonstrated no effect on the cell cycle
profile in either control or NTSR3/sortilin-transfected BON and QGP-1
cells (Figure 2B). In addition, no significant change in apoptosiswas noted in
BON cells transfected with NTSR3/sortilin siRNA as determined by the
Cell Death Detection ELISA (Figure 2C, left). In contrast, NTSR3/sortilin
knockdownQGP-1 cells demonstrated significantly decreased induction of
apoptosis, which may be due to decreased cell number (Figure 2C, right).
Collectively, these findings suggest that knockdown of NTSR3/sortilin
significantly reduced the number of NET cells independent of a decrease in
cell proliferation and induction of cell death.
The Effect of NTSR3/Sortilin Silencing on NET Cell Adhesion
To analyze whether NTSR3/sortilin knockdown alters cell adhesion
which can influence cell number change, we conducted two separate
adhesion assays, which determine binding ability of NET cells to
uncoated culture plates or plates coated with type I collagen. As shown
in Figure 3, the direct binding of NTSR3/sortilin knockdown BON
(Figure 3A) and QGP-1 (Figure 3B) cells to uncoated cell plates was
Figure 1. Expression analysis of NTSR3/sortilin in clinical NET tissues and four NET cell lines. (A) Human normal (nonneoplastic, n = 12)
and NET (n = 21) tissue sections were stained with anti-NTSR3/sortilin antibody. Immunoreactivity scores were determined by
multiplication of the values for staining intensity (0, no staining; 1, weak staining; 2, moderate staining; 3, strong staining) and for
percentage of positive staining cells (0, no positive; 1, 0%-10% positive; 2, 11%-50% positive; 3, 51%-100% positive); *P b .05 versus
normal tissue. (B) Representative images are shown for IgG (upper) or NTSR3/sortilin (bottom) staining in normal and lung NET tissues. (C)
Relative expression of mRNA levels for NTS (left) and NTSR3/sortilin (right) in NET cells was assessed by qRT-PCR (*P b .05 versus BON).
(D) Analysis of protein expression for NTS, NTSR3/sortilin, and β-actin in NET cells was performed by Western blot analysis. β-Actin was
used as an internal control for protein loading.
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significantly decreased. Moreover, knockdown of NTSR3/sortilin in
BON (Figure 3C) and QGP-1 (Figure 3D) cells also demonstrated
lower numbers of attached cells on type I collagen–coated plates
compared with control cells. These data indicate that knockdown of
NTSR3/sortilin decreases adhesion of NET cells.
The Effect of NTSR3/Sortilin on NET Cell Migration
To further delineate the role of NTSR3/sortilin on cell migration, we
examined the effect of NTSR3/sortilin knockdown using a Boyden
chamber migration assay with type I collagen–coated Transwells.
NTSR3/sortilin silencing decreased the migratory potential of BON
cells at 24 (Figure 4A) and 48 (Figure 4B) hours, respectively.
Additionally, the migration of QGP-1 cells was also significantly
suppressed by NTSR3/sortilin knockdown at 24 (Figure 4C) and 48
(Figure 4D) hours.
Moreover, we have verified the activation levels of cell
migratory-related signaling pathways such as FAK and Src, which
facilitate cell movement, cell cycle progression, and cell survival inmany
cancer cells [23–25]. In accordance with cell adhesion and migration,
phosphorylation of FAK and Src was dramatically reduced by
knockdown of NTSR3/sortilin in BON and QGP-1 cells (Figure 5).
Taken together, these findings suggest thatNTSR3/sortilin knockdown
inhibits cell migration of NET cells, in part, through a decrease of FAK
and Src activation.
Discussion
It is becoming increasingly evident that NTS signaling components,
in particular, NTS and/or NTSR1, are overexpressed in various types
of cancers and that activation of this signaling is associated with
cancer progression and metastases [8–10]. We also found that NTS
[19] and NTSR1 [9] play a role in tumorigenic function such as cell
proliferation, anchorage-independent growth, cell migration, and
invasion in NETs. Recently, it has also been reported that increased
expression level of NTSR3/sortilin is found in some human cancer
cells and tissues [13,15–18]. Notably, elevated protein level of
NTSR3/sortilin was noted in invasive breast ductal carcinomas and
was closely associated lymph node invasion [17]. In addition, the level
of NTSR3/sortilin in high-grade gliomas and aggressive prostate
cancers was higher than those in normal and low-grade (or indolent)
tumor tissues [16,18]. Higher expression of NTSR3/sortilin, as well
as the ectopic expression of NTS, was also examined in pituitary
adenomas [15]. In our current study, we found that NTSR3/sortilin
protein is strongly expressed in a majority of NET clinical samples
and that their staining was intensely noted in the cytoplasm of NET
cells. Along with breast cancers, gliomas, and pituitary adenomas,
increased level of NTSR3/sortilin is correlated with tumor occur-
rence, indicating that this protein may be involved in tumorigenic
characteristics and aggressiveness of several cancers including NETs.
Together, strong staining of NTSR3/sortilin in the cytoplasm is in
Figure 2. The effect of NTSR3/sortilin knockdown on proliferation and survival of NET cells. (A) Equal numbers of BON and QGP-1 cells
transfected with siRNA against control or NTSR3/sortilin were plated in 24-well plates. Cell numbers were counted in triplicate after 48-
and 96-hour incubation using a cell counter (left; *P b .05 versus control siRNA). Expression levels of PCNA, a marker for proliferation, or
PARP, a marker for apoptosis, and NTSR3/sortilin were measured by Western blotting using siRNA-transfected NET cells (right). (B) Flow
cytometry analysis with siRNA-transfected BON and QGP-1 cells. The percentage of cells in G1, S, and G2/M phases is shown.
(C) Apoptosis assays were performed in quadruplicate using Cell Death Detection ELISAplus (Roche, Indianapolis, IN).
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accordance with previous reports [26,27] that 5% to 10% of NTSR3/
sortilin is detected at the cell surface and NTSR3/sortilin is mainly
associated with the Golgi apparatus, vesicular organelles, and saccules
of endoplasmic reticulum, suggesting the function of NTSR3/sortilin
in intracellular sorting processes.
It has been reported that NTS stimulated cell proliferation of stable
NTSR3/sortilin CHO and immortalized human microglia-SV40
cells through NTSR3/sortilin [28,29]. In addition, NTSR3/sortilin
leads to NTS-induced migration in human microglial cells and
human pancreatic ductal adenocarcinoma [30–32]. In addition to
functioning as a receptor for NTS, NTSR3/sortilin has multiple other
functions and regulates numerous biological processes. NTSR3/
sortilin has multiple binding partners such as a lipoprotein lipase,
proneurotrophins (e.g., pro-NGF and precursor of brain-derived
neurotrophic factor), and the p75NTR as a receptor or co-receptor.
Recently, it was reported that NTSR3/sortilin is involved in
promotion of cell migration and invasion by pro-NGF in melanoma
and breast cancer cell lines with p75NTR and tropomyosin (or
tyrosine) receptor kinase A, respectively [33,34]. In addition, Roselli
and colleagues [17] showed that knockdown of NTSR3/sortilin
decreased cell number by reducing cell adhesion without affecting cell
proliferation and survival of breast cancer cells. Furthermore, they
found that NTSR3/sortilin silencing inhibited cell migration and
invasion only in highly invasive and triple-negative MDA-MB-231
cells [17]. Similarly, our data showed that knockdown of NTSR3/
sortilin decreased the adhesion of NET cells without significant
change of cell growth or cell death. Moreover, NTSR3/sortilin
knockdown reduced cell migration in both BON and QGP-1 cells.
It is well established that activation of NTSR1 is involved in cell
proliferation, adhesion, migration, and invasion similar to the effect of
NTSR3/sortilin in this study [8–10]. Moreover, in our previous study,
increased expression of NTSR1 was assessed in the same clinical NET
samples [9]. Additionally, with NTS treatment, NTSR1-NTSR3/
sortilin can interact to form a complex and become internalized [8].
Based on this relationship, we determined whether there was a
correlation between NTSR1 and NTSR3/sortilin expression and found
no correlation in the expression in the NET samples. Furthermore, the
silencing effect of NTSR3/sortilin in BON and QGP-1 cells on cell
adhesion and migration is identical despite the distinction of NTSR1
expression (moderate and no NTSR1 transcripts in BON and QGP-1
cells, respectively). In line with the above evidence, our findings suggest
that NTSR3/sortilin may be involved in NET cell adhesion and
migration that is unrelated to NTSR1.
Nonreceptor tyrosine kinases FAK and Src have various cellular
functions, and their activation promotes cell motility, cell cycle
progression, and cell survival [23–25]. Numerous studies have shown
Figure 3. The influence of NTSR3/sortilin knockdown on NET cell adhesion. The same number of siRNA-transfected BON (A, C) and
QGP-1 (B, D) cells was added directly onto cell culture plates for 6 hours (A, B) or type I collagen–coated plates for 30 minutes (C, D). The
attached cells were fixed and then stained with crystal violet. Microscopic examination of the attached BON and QGP-1 cells in 48-well
plates (left). The number of attached cells was counted in triplicate, and the mean values were determined (right; *P, b .05 versus control
siRNA).
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that FAK and Src kinases are activated in tumor cells and that this
activation facilitates tumor growth, invasion, and metastasis [23–25].
Recently, it has been shown that the soluble form of NTSR3/sortilin
leads to an increase of FAK- and Src-dependent activation of the PI3
kinase pathway in the HT29 human colon cancer cells line [35].
Decreased phosphorylation of FAK and Src by NTSR3/sortilin
knockdown was also found in breast cancer cells [17]. Consistent with
these findings, we also observed decreased activation of FAK and Src
with inhibited expression of NTSR3/sortilin, suggesting that the
inhibitory effect of NTSR3/sortilin on cell adhesion and migration
may be mediated by FAK and Src.
As noted above, NTSR3/sortilin functions as a (co)receptor for
multiple factors including NTS and pro-NGF. In our study, we
determined the effect of NTSR3/sortilin by gene knockdown alone
without treatment of NTS or proneurotrophin. Although further
work is needed to elucidate the detailed molecular mechanisms for
these effects and precise binding partners, our current data suggest
that NTSR3/sortilin contributes to tumorigenesis of NETs.
Conclusions
In summary, our data demonstrate that NTSR3/sortilin is signifi-
cantly overexpressed in human NET patient tissues. We have also
shown that inhibition of NTSR3/sortilin suppressed NET cell
adhesion and migration using BON and QGP-1 cells. Our findings
suggest a potential role for NTSR3/sortilin in NET tumorigenesis
and a basis to explore NTSR3/sortilin as a novel prognostic marker
and/or therapeutic target of NETs.
Figure 4. The effect of NTSR3/sortilin silencing on migration of NET cells. Migration analyses using Boyden chambers were performed
using control and NTSR3/sortilin knockdown BON cells for 24 (A) and 48 (B) hours. Phase-contrast microscopic images (left) and
quantification of migrated cells observed in four different fields using an inverted microscope (right) are shown (*P b .05 versus control).
Using control and NTSR3/sortilin knockdown QGP-1 cells, migration assays were also performed at 24 (C) and 48 (D) hours.
Figure 5. Regulation of cell adhesion and motility modulating
proteins by NTSR3/sortilin knockdown in NET cells. BON (left) and
QGP-1 (right) cells were transfected with siRNA directed to NTSR3/
sortilin or control. Protein was extracted, and the cell lysates were
analyzed by Western blotting using antibodies against NTSR3/
sortilin, FAK, phospho-FAK (Tyr397), Src, phospho-Src (Tyr416), or
β-actin.
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